Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Opioids

FDA Issues Updated Prescribing Information for Opioids & Over-the-Counter Naloxone

Michele B. Kaufman, PharmD, BCGP  |  June 13, 2023

New prescribing guidance has been issued by the FDA for immediate-release and extended-release/long-acting opioids for pain management. The agency also announced multiple label updates, which include changes to the Boxed Warnings.

Filed under:AnalgesicsDrug Updates Tagged with:FDAopioidPain ManagementPain Syndrome FocusRheumprescribingPrescribing RulesU.S. Food and Drug Administration (FDA)

Opioids Commonly Prescribed for Gout Attacks

Reuters Staff  |  July 9, 2019

NEW YORK (Reuters Health)—Nearly three in 10 patients seeking care at the emergency department (ED) for acute gout will be discharged with a prescription for opioids, new research shows. “Our study suggests a high use of prescription opioid in patients discharged from the ED with a diagnosis of gout, a condition that can be managed…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis Care & ResearchEmergency DepartmentGoutopioidPainPain Management

Annual Meeting Speakers Review Studies Ranging from Opioids to Fibroblasts

Thomas R. Collins  |  December 18, 2018

CHICAGO—Findings on opioid efficacy, serum urate in osteoarthritis and arthrocentesis headlined the top research of the year discussed in the first half of a session at the 2018 ACR/ARHP Annual Meeting. The second half covered basic science findings, including summaries of new insights into the gender bias in autoimmune diseases, platelet microparticles in scleroderma and…

Filed under:Meeting ReportsResearch Rheum Tagged with:2018 ACR/ARHP Annual MeetingarthrocentesisfibroblastsGenderopioid efficacyOsteoarthritisRheumatoid Arthritis (RA)Scleroderma

FDA Expands Safety Measures for Immediate Release Opioids

Michele B. Kaufman, PharmD, BCGP  |  October 2, 2018

The FDA has expanded the new Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) to include immediate release opioids. The program, which also includes extended release and long acting opioids, will provide education to prescribers and healthcare professionals…

Filed under:AnalgesicsDrug Updates Tagged with:FDAimmediate release opioidsOpioidsREMSSafetyU.S. Food and Drug Administration (FDA)

Nonopioid Medication May Be as Effective as Opioids for Chronic Pain

Lara C. Pullen, PhD  |  April 16, 2018

A recent study compared the efficacy of opioids with nonopioid pain treatments in patients with chronic back pain and hip or knee osteoarthritis. After 12 months, researchers found that treatment with opioids was not superior to treatment with nonopioid medication, with only minor differences in patients’ functional responses to the medications…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painopioidopioid alternativesPainPain Management

Opioids No Better Than NSAIDs for Chronic Back or Arthritis Pain

Lisa Rapaport  |  March 7, 2018

(Reuters Health)—Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests. And opioids are no better than these other drugs at reducing how much pain interferes with daily activities, such as walking, working, sleeping or enjoying…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painhiphip painKnee Osteoarthritis (OA)Nonsteroidal anti-inflammatory drugs (NSAIDs)NSAIDsOpioidsosteoarthritis (OA)PainPain Management

Wal-Mart Launches Program to Safely Dispose of Unused Opioids

Reuters Staff  |  January 17, 2018

NEW YORK (Reuters)—Wal-Mart Stores Inc on Wednesday said it will provide customers filling prescriptions for opioids with a packet of powder that will help them dispose of leftover medication in order to help curb misuse and abuse. The company said patients filling any new class II opioid prescriptions at its pharmacies will receive a free…

Filed under:Drug Updates Tagged with:leftover medication disposal programnational opioid addiction epidemicopioid crisis

Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs

Deena Beasley  |  November 17, 2017

(Reuters)—The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid Services (CMS) said…

Filed under:Drug Updates Tagged with:drug costsMedicareOpioidsprescription drug costsTrump administration

Trump Declares Opioids a U.S. Public Health Emergency

Yasmeen Abutaleb and Jeff Mason  |  October 27, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump declared the opioid crisis a public health emergency on Thursday, stopping short of a national emergency declaration he promised months ago that would have freed up more federal money. Responding to a growing problem wreaking havoc in rural areas, Trump’s declaration will redirect federal resources and loosen regulations to combat…

Filed under:Drug Updates Tagged with:Fentanylnational opioid addiction epidemicopioid crisisprescription painkillersU.S. public health emergency

FDA Sets Stricter Requirements for Immediate-Release Opioids to Prevent Misuse & Abuse

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2017

The FDA is expanding its Risk Evaluation and Mitigation Strategy (REMS) to include manufacturers of immediate-release opioids. The makers of these drugs will soon be required to provide training and education to healthcare professionals on the proper prescription and use of the drugs for pain management…

Filed under:AnalgesicsDrug Updates Tagged with:FDAopioidOpioid abuseREMSU.S. Food and Drug Administration (FDA)

  • 1
  • 2
  • 3
  • …
  • 20
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences